Agilent Technologies Inc Stock Price, News & Analysis

Agilent Technologies (NYSE: A) has announced that its new Infinity III LC Series liquid chromatography instruments have received the My Green Lab ACT Ecolabel 2.0 certification, becoming the first Agilent instruments to achieve this distinction. The series features energy-efficient workflows, automated tasks, and optimized solvent management to support sustainable laboratory operations. Notable innovations include a modular design allowing Infinity II LC upgrades and the industry-first capability to provide CO2 footprint information to customers. The certification reflects Agilent's commitment to sustainable scientific innovation, helping laboratories reduce their ecological footprint while maintaining high-quality results. The My Green Lab ACT Ecolabel 2.0 represents an evolution in lab product sustainability assessment, using standardized, science-based methods to evaluate environmental impact.

TORM plc (NASDAQ: TRMD) has announced a capital increase through the issuance of 151,581 A-shares at a nominal value of USD 1,515.81. This increase results from the exercise of Restricted Share Units as part of the company's incentive program. The new shares were subscribed for in cash at DKK 0.08 per A-share.

Following the capital increase, TORM's total share capital now stands at USD 984,345.66, consisting of 98,434,564 A-shares, one B-share, and one C-share, each with a nominal value of USD 0.01. The A-shares carry a total of 98,434,564 votes, while the B and C shares have specific voting rights. The new shares are expected to be listed on Nasdaq Copenhagen soon.

TORM plc (NASDAQ: TRMD) has reported an insider transaction involving CEO and Executive Director Jacob Balslev Meldgaard. The executive exercised 33,559 restricted share units at a price of DKK 0.08 per share, totaling DKK 2,684.72. The transaction was executed on May 19, 2025, outside a trading venue.

TORM is a leading carrier of refined oil products, operating a fleet of product tanker vessels with a focus on safety and environmental responsibility. The company, founded in 1889, has its shares listed on both Nasdaq Copenhagen and Nasdaq New York.

Agilent Technologies (NYSE: A) announced that CEO Padraig McDonnell and CFO Bob McMahon will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 4, 2025, at 10:30 a.m. Eastern in New York City. Investors and interested parties can access a live audio webcast and replay of the presentation through the Agilent Investor Relations website.

Crawford & Company (NYSE: CRD-A and CRD-B) has announced its quarterly dividend declaration following its regular board meeting on May 7, 2025. The company will distribute a dividend of $0.07 per share for both Class A and Class B Common Stock. The dividend will be paid on June 6, 2025, to shareholders who are on record as of the market close on May 23, 2025.

TORM plc (NASDAQ: TRMD) has announced a capital increase through the issuance of 18,769 A-shares, with a nominal value of USD 187.69, following the exercise of Restricted Share Units as part of its incentive program. The new shares were subscribed for in cash at DKK 0.08 per A-share.

The new ordinary shares will carry standard rights, including dividend eligibility from the issuance date, and are expected to be listed on Nasdaq Copenhagen. Following this capital increase, TORM's total share capital stands at USD 982,829.85, consisting of 98,282,983 A-shares, one B-share, and one C-share, each with a USD 0.01 par value. The A-shares carry 98,282,983 votes, while the B and C shares maintain specific voting rights.

Agilent Technologies (NYSE: A) has announced its participation at the AACR Annual Meeting 2025 in Chicago, showcasing innovative cancer research solutions. The company unveiled three new Avida DNA Cancer Panels for ultra-sensitive detection of cancer genomic alterations from liquid biopsies, featuring a streamlined 5-hour workflow.

Key highlights include partnerships with Tagomics for their Interlace Multiomics assay integration with Agilent's SureSelect Cancer CGP assay, and collaboration with Roswell Park Cancer Center for the SureSelect Cancer Pan Heme Assay. Additionally, Agilent announced a strategic partnership with Abcam for IHC Companion Diagnostics development using Abcam's portfolio of over 10,000 recombinant monoclonal antibodies.

Agilent Technologies (NYSE: A) has received European IVDR certification for its PD-L1 IHC 22C3 pharmDx assay as a Companion Diagnostic (CDx) for gastric or gastroesophageal junction (GEJ) adenocarcinoma patients. The certification aids in identifying patients eligible for KEYTRUDA® therapy.

The assay is now IVDR certified for seven cancer indications, including non-small cell lung cancer, urothelial carcinoma, esophageal cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and cervical cancer. It remains the only IVDR-certified CDx for gastric and GEJ adenocarcinoma patients seeking KEYTRUDA treatment.

This expansion is particularly significant given that gastric cancer affected over 130,000 Europeans in 2022, with a 5-year survival rate of 26% in Europe. The assay works exclusively with Agilent's Autostainer Link 48 advanced staining solution.